Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $310.75

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Buy” from the twenty-one analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $310.75.

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Barclays lowered their price target on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. TD Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Jefferies Financial Group dropped their price target on Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $327.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, September 1st.

Insider Activity

In other news, Director Jean-Jacques Bienaimé bought 2,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director owned 2,900 shares of the company’s stock, valued at approximately $714,357. This trade represents a 222.22% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 41.6% during the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares in the last quarter. Sei Investments Co. grew its stake in shares of Ascendis Pharma A/S by 24.8% during the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after acquiring an additional 69,673 shares during the period. Fred Alger Management LLC increased its holdings in Ascendis Pharma A/S by 106.3% in the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock worth $75,084,000 after acquiring an additional 181,408 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in Ascendis Pharma A/S by 68.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after acquiring an additional 91,822 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its holdings in Ascendis Pharma A/S by 243.0% in the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock worth $56,907,000 after acquiring an additional 178,415 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $230.05 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99. The firm has a market cap of $14.35 billion, a price-to-earnings ratio of 17.85 and a beta of 0.35. The business has a 50-day simple moving average of $251.08 and a two-hundred day simple moving average of $242.21. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. On average, analysts expect that Ascendis Pharma A/S will post 3.69 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.